Toragen launches Phase 1 trial of TGN-S11 in HPV-associated cancer

Toragen, a San Diego-based clinical-stage biotechnology company, has launched a Phase 1 clinical trial to evaluate its initial drug candidate, TGN-S11, targeting cancers instigated by ... Read More